Comparative assessment of a COVID-19 vaccine after technology transfer to Iran from critical quality attributes to clinical and immunogenicity aspects

Comparative assessment of a COVID-19 vaccine after technology transfer to Iran from critical quality attributes to clinical and immunogenicity aspects

Abstract During COVID-19 pandemic, international pharmaceutical companies put effort to build global manufacturing networks for vaccines. Soberana Plus vaccine, a recombinant protein based vaccine (RBD dimer), with the trade name of PastoCovac Plus in Iran, is based on a protein subunit platform in...

Full description

Saved in:
Bibliographic Details
Main Authors: Delaram Doroud, Mona Sadat Larijani, Alireza Biglari, Fatemeh Ashrafian, Talieh Sabouni, Sana Eybpoosh, Vicente Verez-Bencomo, Yury Valdés-Balbín, Dagmar García-Rivera, Yaneli Herrera-Rojas, Yanet Climent-Ruiz, Darielys Santana-Mederos, Amitis Ramezani
Format: Article
Language:English
Published: Nature Portfolio 2024-11-01
Series:Scientific Reports
Subjects:
PastoCovac Plus
Soberana Plus
RBD dimer
Protein-based vaccine
Iran
Online Access:https://doi.org/10.1038/s41598-024-77331-8
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41598-024-77331-8

Similar Items